

Eric Van Ganse

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5967285/publications.pdf>

Version: 2024-02-01

105
papers

3,668
citations

117453

34
h-index

155451

55
g-index

116
all docs

116
docs citations

116
times ranked

4413
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrated care pathways for airway diseases (AIRWAYS-ICPs). <i>European Respiratory Journal</i> , 2014, 44, 304-323.	3.1	154
2	Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997-2003. <i>British Journal of Clinical Pharmacology</i> , 2005, 60, 543-551.	1.1	153
3	Disease-specific health-related quality of life questionnaires for heart failure: a systematic review with meta-analyses. <i>Quality of Life Research</i> , 2009, 18, 71-85.	1.5	153
4	Opportunities to diagnose chronic obstructive pulmonary disease in routine care in the UK: a retrospective study of a clinical cohort. <i>Lancet Respiratory Medicine</i> , 2014, 2, 267-276.	5.2	149
5	Persistent asthma: disease control, resource utilisation and direct costs. <i>European Respiratory Journal</i> , 2002, 20, 260-267.	3.1	127
6	The PAIN Study: Paracetamol, Aspirin and Ibuprofen New Tolerability Study. <i>Clinical Drug Investigation</i> , 1999, 18, 89-98.	1.1	126
7	Variations and increase in use of statins across Europe: data from administrative databases. <i>BMJ: British Medical Journal</i> , 2004, 328, 385-386.	2.4	109
8	What We Mean When We Talk About Adherence in Respiratory Medicine. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2016, 4, 802-812.	2.0	104
9	Ongoing pharmaceutical reforms in France. <i>Applied Health Economics and Health Policy</i> , 2010, 8, 7-24.	1.0	97
10	Effects of antihistamines in adult asthma: a meta-analysis of clinical trials. <i>European Respiratory Journal</i> , 1997, 10, 2216-2224.	3.1	95
11	Influence of patients' characteristics and disease management on asthma control. <i>Journal of Allergy and Clinical Immunology</i> , 2006, 117, 1404-1410.	1.5	83
12	Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study. <i>Current Medical Research and Opinion</i> , 2005, 21, 1389-1399.	0.9	76
13	Costs associated with persistent allergic rhinitis are reduced by levocetirizine. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2005, 60, 788-794.	2.7	70
14	Influence of lansoprazole treatment on diazepam plasma concentrations. <i>Clinical Pharmacology and Therapeutics</i> , 1992, 52, 458-463.	2.3	66
15	Compliance in depressed patients treated with fluoxetine or amitriptyline. <i>International Clinical Psychopharmacology</i> , 1998, 13, 11-18.	0.9	64
16	Quality of Life during Pollen Season in Patients with Seasonal Allergic Rhinitis with or without Asthma. <i>International Archives of Allergy and Immunology</i> , 2005, 136, 281-286.	0.9	58
17	Adherence to treatment regimen in depressed patients treated with amitriptyline or fluoxetine. <i>Journal of Affective Disorders</i> , 2001, 65, 243-252.	2.0	55
18	Pharmacovigilance of drug allergy and hypersensitivity using the ENDA "DAHD database and the GALILEO platform. The Galenda project. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2009, 64, 194-203.	2.7	53

#	ARTICLE	IF	CITATIONS
19	Prophylactic treatment of grass pollen-induced asthma with cetirizine. <i>Clinical and Experimental Allergy</i> , 1990, 20, 483-490.	1.4	52
20	EuroQol (EQ-5D-5L) Validity in Assessing the Quality of Life in Adults With Asthma: Cross-Sectional Study. <i>Journal of Medical Internet Research</i> , 2019, 21, e10178.	2.1	52
21	Asthma-related resource use and cost by GINA classification of severity in three European countries. <i>Respiratory Medicine</i> , 2006, 100, 140-147.	1.3	50
22	Nutrition economics “characterising the economic and health impact of nutrition. <i>British Journal of Nutrition</i> , 2011, 105, 157-166.	1.2	49
23	Management of asthma in patients supervised by primary care physicians or by specialists. <i>European Respiratory Journal</i> , 2006, 27, 42-50.	3.1	47
24	Asthma patients' self-reported behaviours toward inhaled corticosteroids. <i>Respiratory Medicine</i> , 2009, 103, 1366-1375.	1.3	47
25	Comparison of national administrative and commercial databases to monitor expenditure and costs of statins across Europe. <i>European Journal of Clinical Pharmacology</i> , 2004, 60, 503-511.	0.8	45
26	Frequency of comorbidities in chronic obstructive pulmonary disease, and impact on all-cause mortality: A population-based cohort study. <i>Respiratory Medicine</i> , 2016, 117, 33-39.	1.3	45
27	Comparative Tolerability of Paracetamol, Aspirin and Ibuprofen for Short-Term Analgesia in Patients with Musculoskeletal Conditions: Results in 4291 Patients. <i>Clinical Rheumatology</i> , 2002, 21, 28-31.	1.0	43
28	Correlates of adherence to respiratory drugs in COPD patients. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2010, 19, 148-154.	2.5	43
29	Risk factors for adverse events in analgesic drug users: results from the PAIN study. <i>Pharmacoepidemiology and Drug Safety</i> , 2003, 12, 601-610.	0.9	41
30	Galectin-10 mRNA is overexpressed in peripheral blood of aspirin-induced asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2007, 63, 071018035620002-???	2.7	41
31	Comparative Safety and Effectiveness of Oral Anticoagulants in Nonvalvular Atrial Fibrillation. <i>Stroke</i> , 2020, 51, 2066-2075.	1.0	41
32	Asthmatic patients'™ poor awareness of inadequate disease control: a pharmacy-based survey. <i>Annals of Allergy, Asthma and Immunology</i> , 2007, 98, 146-152.	0.5	40
33	Evidence on the global measurement model of the Minnesota Living with Heart Failure Questionnaire. <i>Quality of Life Research</i> , 2013, 22, 2675-2684.	1.5	38
34	Earlier disability of the patients followed in Multiple Sclerosis centers compared to outpatients. <i>Multiple Sclerosis Journal</i> , 2009, 15, 251-257.	1.4	37
35	Actual use of inhaled corticosteroids and risk of hospitalisation: a case-control study. <i>European Journal of Clinical Pharmacology</i> , 1997, 51, 449-454.	0.8	35
36	Responses of the Immune System to Injury. <i>Toxicologic Pathology</i> , 2000, 28, 479-481.	0.9	35

#	ARTICLE	IF	CITATIONS
37	Cost-effectiveness of pravastatin in secondary prevention of coronary heart disease: comparison between Belgium and the United States of a projected risk model. <i>Atherosclerosis</i> , 1998, 137, S111-S116.	0.4	34
38	Gastrointestinal Tolerability of Ibuprofen Compared with Paracetamol and Aspirin at Over-the-Counter Doses. <i>Journal of International Medical Research</i> , 2002, 30, 301-308.	0.4	33
39	Association between asthma control in children and loss of workdays by caregivers. <i>Annals of Allergy, Asthma and Immunology</i> , 2004, 93, 265-271.	0.5	33
40	Quality of asthma care: results from a community pharmacy based survey. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2005, 60, 1505-1510.	2.7	33
41	Ineffectiveness of lipid-lowering therapy in primary care. <i>British Journal of Clinical Pharmacology</i> , 2005, 59, 456-463.	1.1	33
42	Measuring medication adherence in asthma: Development of a novel self-report tool. <i>Psychology and Health</i> , 2017, 32, 1288-1307.	1.2	30
43	Real-life use of fluticasone propionate/salmeterol in patients with chronic obstructive pulmonary disease: a French observational study. <i>BMC Pulmonary Medicine</i> , 2014, 14, 56.	0.8	29
44	Prescribed therapy for asthma: therapeutic ratios and outcomes. <i>BMC Family Practice</i> , 2015, 16, 49.	2.9	28
45	Inappropriate asthma therapy—a tale of two countries: a parallel population-based cohort study. <i>Npj Primary Care Respiratory Medicine</i> , 2016, 26, 16076.	1.1	28
46	Asthma medications and disease exacerbations: an epidemiological study as a method for asthma surveillance. <i>European Respiratory Journal</i> , 1995, 8, 1856-1860.	3.1	27
47	Mixed Dyslipidemia Among Patients Using Lipid-Lowering Therapy in French General Practice: An Observational Study. <i>Clinical Therapeutics</i> , 2007, 29, 1671-1681.	1.1	27
48	Does adherence to inhaled corticosteroids predict asthma-related outcomes over time? A cohort study. <i>European Respiratory Journal</i> , 2019, 54, 1900901.	3.1	26
49	Correlates of quality of life in patients with asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2005, 94, 473-479.	0.5	25
50	Asthma drug ratios and exacerbations: claims data from universal health coverage systems. <i>European Respiratory Journal</i> , 2014, 43, 1378-1386.	3.1	24
51	The REal Life EVIDence AssessmeNt Tool (RELEVANT): development of a novel quality assurance asset to rate observational comparative effectiveness research studies. <i>Clinical and Translational Allergy</i> , 2019, 9, 21.	1.4	24
52	Level of Control and Hospital Contacts in Persistent Asthma. <i>Journal of Asthma</i> , 2001, 38, 637-643.	0.9	23
53	Medication use and disease control of asthmatic patients in Flanders: A cross-sectional community pharmacy study. <i>Respiratory Medicine</i> , 2006, 100, 1407-1414.	1.3	22
54	Asthma patients's™ perception of their ability to influence disease control and management. <i>Annals of Allergy, Asthma and Immunology</i> , 2009, 102, 378-384.	0.5	22

#	ARTICLE	IF	CITATIONS
55	Mapping the Asthma Care Process: Implications for Research and Practice. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2016, 4, 868-876.	2.0	22
56	Na ⁺ -H ⁺ exchange in the process of glucose-induced insulin release from the pancreatic B-cell. Effects of amiloride on ⁸⁶ Rb, ⁴⁵ Ca fluxes and insulin release. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1986, 886, 448-456.	1.9	21
57	Impact of asthma on women and men: Comparison with the general population using the EQ-5D-5L questionnaire. <i>PLoS ONE</i> , 2018, 13, e0202624.	1.1	21
58	Assessing Asthma Management from Interviews of Patients and Family Physicians. <i>Journal of Asthma</i> , 1997, 34, 203-209.	0.9	20
59	A large simple clinical trial prototype for assessment of OTC drug effects using patient-reported data. <i>Pharmacoepidemiology and Drug Safety</i> , 2005, 14, 249-255.	0.9	20
60	Long-Term Inhaled Corticosteroid Adherence in Asthma Patients with Short-Term Adherence. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2016, 4, 890-899.e2.	2.0	20
61	Inhaled Corticosteroid Adherence Patterns in a Longitudinal Asthma Cohort. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 448-456.e2.	2.0	20
62	Quality standards in respiratory real-life effectiveness research: the REal Life EVIDence Assessment Tool (RELEVANT): report from the Respiratory Effectiveness Group of the European Academy of Allergy and Clinical Immunology Task Force. <i>Clinical and Translational Allergy</i> , 2019, 9, 20.	1.4	20
63	Factors affecting adherence to asthma treatment: patient and physician perspectives. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2003, 12, 46-51.	2.5	19
64	The Relationship Between Real-World Inhaled Corticosteroid Adherence and Asthma Outcomes: A Multilevel Approach. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 626-634.	2.0	19
65	Long-term achievement of the therapeutic objectives of lipid-lowering agents in primary prevention patients and cardiovascular outcomes: An observational study. <i>Atherosclerosis</i> , 2006, 185, 58-64.	0.4	18
66	Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis. <i>Respiratory Research</i> , 2021, 22, 135.	1.4	18
67	The safety of drugs for OTC use: what evidence is required for an NSAID switch?. <i>Pharmacoepidemiology and Drug Safety</i> , 2002, 11, 577-584.	0.9	17
68	Correlates of LDL-cholesterol goal attainment in patients under lipid lowering therapy. <i>Atherosclerosis</i> , 2008, 199, 368-377.	0.4	16
69	Assessment of the safety of long-acting β_2 -agonists in routine asthma care: the ASTRO-LAB protocol. <i>Npj Primary Care Respiratory Medicine</i> , 2015, 25, 15040.	1.1	15
70	Influence of sociodemographic factors on quality of life during pollen season in seasonal allergic rhinitis patients. <i>Annals of Allergy, Asthma and Immunology</i> , 2005, 95, 26-32.	0.5	14
71	Mixed dyslipidemias in primary care patients in France. <i>Vascular Health and Risk Management</i> , 2012, 8, 247.	1.0	14
72	How appropriate is asthma therapy in general practice?. <i>Fundamental and Clinical Pharmacology</i> , 2005, 19, 107-115.	1.0	11

#	ARTICLE	IF	CITATIONS
73	Cost-effectiveness of raising HDL cholesterol by adding prolonged-release nicotinic acid to statin therapy in the secondary prevention setting: a French perspective. <i>International Journal of Clinical Practice</i> , 2007, 61, 1805-1811.	0.8	11
74	Factors associated with early adherence to tiotropium in chronic obstructive pulmonary disease. <i>Chronic Respiratory Disease</i> , 2013, 10, 11-18.	1.0	11
75	Level of Asthma Controller Therapy Before Admission to the Hospital. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2016, 4, 877-883.	2.0	11
76	Effects of short- and long-acting beta-agonists on asthma exacerbations: a prospective cohort. <i>Annals of Allergy, Asthma and Immunology</i> , 2020, 124, 254-260.	0.5	11
77	Asthma and allergy medication use and costs among pediatric primary care patients on asthma controller therapy. <i>Pediatric Allergy and Immunology</i> , 2006, 17, 620-628.	1.1	10
78	Changes in Persistent Asthma Care and Outcomes From 2006 to 2016 in France. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1858-1867.	2.0	10
79	Correlates of quality of life of pre-obese and obese patients: a pharmacy-based cross-sectional survey. <i>BMC Public Health</i> , 2009, 9, 337.	1.2	9
80	Vitamin D supplementation in a healthy, middle-aged population: actual practices based on data from a French comprehensive regional health-care database. <i>European Journal of Clinical Nutrition</i> , 2013, 67, 1133-1137.	1.3	9
81	Relative exposure to controller therapy and asthma exacerbations: a validation study in community pharmacies. <i>Pharmacoepidemiology and Drug Safety</i> , 2014, 23, 958-964.	0.9	9
82	Limited treatment adaptation despite poor asthma control in asthma patients treated with inhaled corticosteroids. <i>Journal of Asthma</i> , 2016, 53, 76-85.	0.9	9
83	Temporal trends in healthcare resource use and associated costs of patients with cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2022, 21, 88-95.	0.3	9
84	Dispensing of antibiotics, antitussives and mucolytics to asthma patients: A pharmacy-based observational survey. <i>Respiratory Medicine</i> , 2008, 102, 57-63.	1.3	8
85	Prevalence of low high-density lipoprotein cholesterol and hypertriglyceridaemia in patients treated with hypolipidaemic drugs. <i>Archives of Cardiovascular Diseases</i> , 2009, 102, 43-50.	0.7	8
86	Health problems most commonly diagnosed among young female patients during visits to general practitioners and gynecologists in France before the initiation of the human papillomavirus vaccination program. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 261-268.	0.9	8
87	Prescription of antibiotics and anxiolytics/hypnotics to asthmatic patients in general practice: a cross-sectional study based on French and Italian prescribing data. <i>BMC Family Practice</i> , 2015, 16, 14.	2.9	8
88	<p>Dual versus triple therapy in patients hospitalized for COPD in France: a claims data study</p>. <i>International Journal of COPD</i> , 2019, Volume 14, 1839-1854.	0.9	8
89	Heterogeneity of the pharmacologic treatment of allergic rhinitis in Europe based on MIDAS and OTCims platforms. <i>Clinical and Experimental Allergy</i> , 2021, 51, 1033-1045.	1.4	8
90	Long-Term Treatment Acceptance. <i>Patient</i> , 2012, 5, 239-249.	1.1	8

#	ARTICLE	IF	CITATIONS
91	Mortality and Respiratory-Related Hospitalizations in Idiopathic Pulmonary Fibrosis Not Treated With Antifibrotics. <i>Frontiers in Medicine</i> , 2021, 8, 802989.	1.2	8
92	Patient-reported Adverse Events Under Asthma Therapy: A Community Pharmacy-based Survey. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 82, 167-172.	2.3	7
93	Respiratory Medication Adherence: Toward a Common Language and a Shared Vision. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2016, 4, 799-801.	2.0	7
94	Factors influencing dispensing of psychotropic medications to patients with asthma: a community pharmacy-based survey. <i>Annals of Allergy, Asthma and Immunology</i> , 2008, 100, 230-236.	0.5	6
95	Asthma exacerbations and socio-economic status in French adults with persistent asthma: A prospective cohort study. <i>Journal of Asthma</i> , 2018, 55, 1043-1051.	0.9	6
96	Primary care physicians' behaviors towards risk of iatrogenesis in elderly patients. <i>European Journal of Clinical Pharmacology</i> , 2006, 62, 563-570.	0.8	5
97	Use of margarine enriched in phytosterols by patients at high cardiovascular risk and treated by hypolipidemic drugs. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2007, 17, 657-665.	1.1	5
98	Non-interventional Research and Usual Care: Definition, Regulatory Aspects, Difficulties and Recommendations. <i>Therapie</i> , 2008, 63, 103-106.	0.6	5
99	Evaluation of Apixaban in stroke and systemic embolism prevention in patients with nonvalvular atrial fibrillation in clinical practice Setting in France, rationale and design of the NAXOS: SNIIRAM study. <i>Clinical Cardiology</i> , 2019, 42, 851-859.	0.7	5
100	Asthma-Related Costs Relative to Severity and Control in General Practice. <i>Pediatric Asthma, Allergy and Immunology</i> , 2005, 18, 36-45.	0.2	4
101	<p></p>Impact of Therapy Persistence on Exacerbations and Resource Use in Patients Who Initiated COPD Therapy</p>. <i>International Journal of COPD</i> , 2019, Volume 14, 2905-2915.	0.9	4
102	The Inhaler Technique Questionnaire (InTeQ): Development and Validation of a Brief Patient-Reported Measure. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 2591.	1.2	4
103	Projet d'éducation du patient asthmatique et proposition d'une méthode d'évaluation. <i>Pédagogie Médicale</i> , 2007, 8, 30-43.	0.2	2
104	Use of Oral Xanthines in the Elderly and Extent of "Silent Risks": Information from a Drug Dispensing Database. , 1997, 6, 135-136.		0
105	Severe hypertriglyceridaemia in patients treated with lipid-modifying agents. <i>Diabetes and Metabolism</i> , 2012, 38, 277-279.	1.4	0